Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Finished Drug Prices
NA
1. Glyceroltriheptanoate
2. Glyceryl Triheptanoate
1. 620-67-7
2. Propane-1,2,3-triyl Triheptanoate
3. Trienanthoin
4. Trioenanthoin
5. Glyceryl Triheptanoate
6. Glycerol Triheptanoate
7. Triheptanoic Glyceride
8. Heptanoin, Tri-
9. Ux007
10. Dermofeel Tc 7
11. Dojolvi
12. Propane-1,2,3-triyl Trisheptanoate
13. 2,3-di(heptanoyloxy)propyl Heptanoate
14. Dub Thg
15. Heptanoic Acid, 1,2,3-propanetriyl Ester
16. Dermofeel Tc-7
17. Ux-007
18. Radiamuls 2375
19. Lanol 37 T
20. Triheptanoin [usan]
21. 2p6o7cfw5k
22. 3-02-00-00769 (beilstein Handbook Reference)
23. Heptanoic Acid, 1,1',1''-(1,2,3-propanetriyl) Ester
24. Triheptanoin (usan)
25. Triheptylin
26. 1,2,3-propanetriyl Triheptanoate
27. Glyceroltriheptanoate
28. Brn 1807724
29. Lanol 37t
30. Einecs 210-647-2
31. Unii-2p6o7cfw5k
32. Trienantin
33. Dojolvi (tn)
34. Glycerol Trienanthate
35. Glyceryl Trienanthate
36. Triheptanoin [mi]
37. Triheptanoin [inn]
38. Ec 210-647-2
39. Triheptanoin [inci]
40. Schembl525618
41. Triheptanoin [who-dd]
42. Glycerol Trienanthate, >=94%
43. Chembl4297585
44. Gtpl11431
45. Dtxsid40862306
46. Propane-1,2,3-triyltriheptanoate
47. Triheptanoin [orange Book]
48. Zinc4521897
49. Ind106011
50. Mfcd00042910
51. Ux 007
52. 1r,2s-(-)-norephedrinehydrochloride
53. Cs-w013852
54. Db11677
55. Hy-w013136
56. Ind 106011
57. Ind-106011
58. Ind106011; Ux007
59. Ls-15081
60. Ft-0757070
61. D11465
62. A868568
63. Q414576
64. W-109093
Molecular Weight | 428.6 g/mol |
---|---|
Molecular Formula | C24H44O6 |
XLogP3 | 7.3 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 23 |
Exact Mass | 428.31378912 g/mol |
Monoisotopic Mass | 428.31378912 g/mol |
Topological Polar Surface Area | 78.9 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 421 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Triheptanoin is a medium chain triglyceride indicated to provide calories and fatty acids to treat long chain fatty acid oxidation disorders (lc-FAODs).
FDA Label
Triheptanoin is a source of medium chain fatty acids for patients with lc-FAODs. It has a moderate duration of action and a wide therapeutic window. Patients should be counselled regarding the risk of feeding tube dysfunction and intestinal malabsorption due to pancreatic insufficiency.
A - Alimentary tract and metabolism
A16 - Other alimentary tract and metabolism products
A16A - Other alimentary tract and metabolism products
A16AX - Various alimentary tract and metabolism products
A16AX17 - Triheptanoin
Absorption
A single 0.3 g/kg dose of triheptanoin reaches a Cmax of 178.9 mol/L, with a Tmax 0.5 h, and an AUC of 336.5 mol\*h/L. A single 0.4 g/kg dose of triheptanoin reaches a Cmax of 259.1 mol/L, with a Tmax 0.8 h, and an AUC of 569.1 mol\*h/L.
Route of Elimination
Triheptanoin is minimally eliminated in the urine.
Clearance
A single dose of 0.3 g/kg results in a mean apparent clearance of 6.05 L/h/kg for heptanoate. A single dose of 0.4 g/kg results in a mean apparent clearance of 4.31 L/h/kg for heptanoate.
Triheptanoin is hydrolysed to heptanoate, which can be further metabolized to -hydroxypentanoate or -hydroxybutyrate.
Due to multiple peak concentrations of the heptanoate metabolite, the half life of triheptanoin could not be determined.
Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with lc-FAODs treated with triheptanoin experienced improvements in hypoglycemia, cardiomyopathy, and rhabdomyolysis.
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-03-13
Pay. Date : 2024-02-16
DMF Number : 39534
Submission : 2024-02-12
Status : Active
Type : II
NDC Package Code : 15894-0041
Start Marketing Date : 2024-01-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26895
Submission : 2013-03-01
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-04-16
Pay. Date : 2024-03-22
DMF Number : 39441
Submission : 2024-03-26
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-03-21
Pay. Date : 2024-01-25
DMF Number : 39430
Submission : 2024-02-08
Status : Active
Type : II
NDC Package Code : 59651-938
Start Marketing Date : 2024-01-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-04-16
Pay. Date : 2024-03-15
DMF Number : 39415
Submission : 2024-03-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39145
Submission : 2024-02-07
Status : Active
Type : II
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Complete
Rev. Date : 2024-03-13
Pay. Date : 2024-02-16
DMF Number : 39534
Submission : 2024-02-12
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-03-21
Pay. Date : 2024-01-25
DMF Number : 39430
Submission : 2024-02-08
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-04-16
Pay. Date : 2024-03-22
DMF Number : 39441
Submission : 2024-03-26
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-04-16
Pay. Date : 2024-03-15
DMF Number : 39415
Submission : 2024-03-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39145
Submission : 2024-02-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26895
Submission : 2013-03-01
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info : RX
Registration Country : USA
Brand Name : DOJOLVI
Dosage Form : LIQUID;ORAL
Dosage Strength : 100% w/w
Packaging :
Approval Date : 2020-06-30
Application Number : 213687
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : DOJOLVI
Dosage Form : LIQUID
Dosage Strength : 100%/W/W
Packaging :
Approval Date :
Application Number : 2512556
Regulatory Info : Prescription
Registration Country : Canada
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?